Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Equity Average (2021 - 2025)

Historic Equity Average for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Q3 2025 value amounting to $449.9 million.

  • Maravai Lifesciences Holdings' Equity Average fell 3503.81% to $449.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.9 million, marking a year-over-year decrease of 3503.81%. This contributed to the annual value of $683.5 million for FY2024, which is 1935.16% down from last year.
  • Maravai Lifesciences Holdings' Equity Average amounted to $449.9 million in Q3 2025, which was down 3503.81% from $499.1 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Equity Average high stood at $902.9 million for Q1 2023, and its period low was $182.3 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $692.6 million (2024), whereas its average is $643.6 million.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Equity Average soared by 22912.38% in 2022 and then crashed by 3559.12% in 2025.
  • Maravai Lifesciences Holdings' Equity Average (Quarter) stood at $499.5 million in 2021, then surged by 74.87% to $873.5 million in 2022, then dropped by 3.71% to $841.1 million in 2023, then decreased by 29.26% to $595.0 million in 2024, then decreased by 24.38% to $449.9 million in 2025.
  • Its Equity Average stands at $449.9 million for Q3 2025, versus $499.1 million for Q2 2025 and $553.7 million for Q1 2025.